Human Recombinant Endostatin Combined with Cisplatin Based Doublets in Treating Patients with Advanced NSCLC and Evaluation by CT Perfusion Imaging

Aims: To study the effectiveness of human recombinant endostatin injection (Endostar®) combined withcisplatin doublets in treating advanced non-small cell lung cancer (NSCLC), and to evaluate outcome by CTperfusion imaging.
Methods: From April 2011 to September 2014, 76 patients with advanced NSCLC whowere treated with platinum-based doublets were divided into group A (36 patients) and group B (40 patients).Endostar® 15mg/day was administered 4 days before chemotherapy and combined with chemotherapy from day5 in group A, and combined with chemotherapy from the first day in Group B. Endostar® in the two groups wasinjected intravenously for 14 days.
Results: Treatment effectiveness in the two groups differed with statisticalsignificance (p<0.05). Effectiveness evaluated by CT perfusion imaging, BF, BV, MTT and PS also demonstratedsignificant differences (all p<0.05). Adverse reactions in the two groups did not significantly vary (p> 0.05).
Conclusions: The response rate with Endostar® administered 4 days before chemotherapy and combined withchemotherapy from day 5 in group A was better than Endostar® combined with chemotherapy from the firstday, and CT perfusion imaging could be a reasonable method for evaluation of patient outcomes.